These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 37012629)

  • 1. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

  • 6. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring for biological medications in inflammatory bowel disease.
    Cogan RC; El-Matary BW; El-Matary WM
    Saudi J Gastroenterol; 2022; 28(5):322-331. PubMed ID: 35343213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
    Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
    Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
    J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.
    Desai DC; Dherai AJ; Strik A; Mould DR
    J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
    Samuels A; Whaley KG; Minar P
    Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
    Schneider C; Stratman S; Choragudi S; Lev-Tov H
    J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
    Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis.
    Manceñido Marcos N; Novella Arribas B; Mora Navarro G; Rodríguez Salvanés F; Loeches Belinchón P; Gisbert JP
    Dig Liver Dis; 2024 Mar; 56(3):421-428. PubMed ID: 37422409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
    Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.